Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer

Genetic Vaccines and Therapy

Volumn 3, Issue , 2005, Pages

  Zhang, Min ^a   Zhang, Xin ^a,b   Bai, Chun Xue ^a   Song, Xian Rang ^b   Chen, Jie ^a   Gao, Lei ^a   Hu, Jie ^a   Hong, Qun Ying ^a   West, Malcolm J ^b   Wei, Ming Q ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Double stranded RNA; Epidermal growth factor receptor; Non small cell lung cancer; RNA interference; Small interference RNA

Indexed keywords

DOUBLE STRANDED RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; RNA SEQUENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BOVINAE; MUS MUSCULUS;

EID: 27344459149     PISSN: 14790556     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-3-5     Document Type: Article

References (34)

1. McLennan G., Roder DM: Lung cancer in Australia. Med J Aust 1989, 150:206-207.
2. Burton RC: Cancer control in Australia: into the 21 (st) Century. Jpn J Clin Oncol 2002, 32:S3-9.
3. Hansen HH: Treatment of advanced non-small cell lung cancer. BMJ 2002, 325:452-453.
4. Cridelli C: Targeted therapies in the treatment of non small cell lung cancer:. Curr Opin Oncol 2004, 26:126-129.
5. Evans TL, Lynch TJ Jr: Lung Cancer. Oncologist 2001, 6:407-414.
6. Weichselbaum RR, Hallahan DE, Beckett MA, et al.: Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994, 54:4266-4269.
7. Gallardo D, Drazan KE, Mcbride WH: Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 1996, 56:4891-4893.
8. Rogulski KR, Kim JH, Kim SH, et al.: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997, 8:73-85.
9. Wakeling AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2002, 2:382-387.
10. Wakeling AE, Guy SP, Woodburn JR, et al.: ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749-5764.
11. Shin DM, Donato NJ, Perez-Soler R, et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001, 7:1204-1213.
12. Ciardiello F, Caputo R, Blanco R, et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD-1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2000, 7:1459-1465.
13. Shawver LK, Slamon D, Ulrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
14. Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001, 37:S16-22.
15. Tamm I, Dorken B, Hartmann G: Antisense therapy in oncology, new hope for an old idea? Lancet 2001, 358:489-497.
16. Elbashir SM, Lendechel W, Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15;188-200.
17. Hammond SM, Caudy AA, Hannon GJ: Post transcriptional gene silencing by double stranded RNA. Nat Rev Genet 2001, 2:110-119.
18. Elbashir SM, Harborth J, Lendechel W, et al.: Duplexes of 21-nucleotides RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
19. Christen RD, Hom DK, Porter DC, et al.: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990, 86:1632-1640.
20. Kroning R, Jones JA, Hom DK, et al.: Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer 1995, 72:615-619.
21. Zhang M, Zhang X, Bai CX, Chen J, Wei MQ: Inhibition of epidermal growth factor receptor (EGFR) by RNA interference in A549 cells. Acta Pharmacol Sin 2004, 25:61-67.
22. Lal A, Glazer CA, Martinson HM, et al.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002, 62:3335-3340.
23. Liu CS, Kong BH, Xia HQ, et al.: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 2001, 3:145-152.
24. Metharom P, Tayra S, Xia HQ, MacMillian J, Shepherd R, Wilcox G, Wei MQ: New bovine lentiviral vectors based on the Jembrana disease virus. J Gene Medicine 2002, 2:176-185.
25. Zhang B, Xia HQ, Cleghorn G, Gobe G, West M, Wei MQ: A highly efficient and consistent method for harvesting large volumes of high titre lentiviral vectors. Gene Therapy 2001, 8:1745-1751.
26. Nagy P, Arndt-Jovin DJ, Jovin TM: Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbBI) and induce apoptosis in erbBI-overexpressing cells. Exp Cell Res 2003, 285:39-49.
27. Nieth C, Priebsch A, Stege A, et al.: Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference(RNAi). FEBS Lett 2003, 545:144-150.
28. Tsai CM, Chang KT, Li L, Perng RP, Yang LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression and epidermal growth factor receptor level in non-small cell lung cancer. Jpn J Cancer Res 2000, 91:213-22.
29. Somasundaram K: Stable RNA interference (RNAi) in mammalian cells. Cancer Biol Ther 2003, 2:211-212.
30. Magne N, Fischel JL, Dubreuil A, et al.: Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002, 86:819-827.
31. Hirata A, Ogawa S, Kometani T: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase 2. Cancer Res 2002, 62:2554-2560.
32. Nakagawa K: Tyrosine kinase inhibitors-solid cancers. Gan To Kagaku Ryoho 2001, 28:608-613.
33. Huang SM, Li J, Armstrong EA, et al.: Modulation of radiation response and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002, 62:4300-4306.
34. Williams KJ, Telfer BA, Stratford IJ, et al.: ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenegraft model. Br J Cancer 2002, 86:1157-1161.